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SUMMARY (246 words) 
Growth differentiation factor 11 (GDF11), a TGF-beta super-family member, is highly 
homologous to myostatin and essential for embryonic patterning and organogenesis. Reports of 
GDF11 effects on adult tissues are conflicting, with some describing anti-aging and pro-
regenerative activities on the heart and skeletal muscle while others opposite or no effects. 
Herein, we sought to determine the in vivo cardiac and skeletal muscle effects of excess 
GDF11. Mice were injected with GDF11 secreting cells, an identical model to that used to 
initially identify the in vivo effects of myostatin.  GDF11 exposure in mice induced whole body 
wasting and profound loss of function in cardiac and skeletal muscle over a 14-day period. Loss 
of cardiac mass preceded skeletal muscle loss. Cardiac histologic and echocardiographic 
evaluation demonstrated loss of ventricular muscle wall thickness, decreased cardiomyocyte 
size and decreased cardiac function 10 days following initiation of GDF11 exposure. Changes in 
skeletal muscle after GDF11 exposure were manifest at day 13 and associated with wasting, 
decreased fiber size, and reduced strength. Changes in cardiomyocytes and skeletal muscle 
fibers were associated with activation of SMAD2, the ubiquitin-proteasome pathway and 
autophagy.  GDF11 over administration in vivo results in cardiac and skeletal muscle loss, 
dysfunction and death. Serum levels of GDF11 by Western blotting were 1.5 fold increased over 
controls. Although GDF11 effects in vivo are likely dose, route, and duration dependent, its 
physiologic changes are similar to myostatin and other Activin receptors ligands. These data 
support that GDF11, like its other closely related TGF-beta family members, induces loss of 
cardiac and skeletal muscle mass and function.    
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INTRODUCTION 
Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-
beta super-family highly homologous to myostatin/GDF8 [17]. GDF11 was first described as a 
secreted factor involved in tooth development [17], axial patterning, and kidney organogenesis  
[15]. More recently, work in adult mice reports regenerative activities for GDF11, with some 
describing it as the “elixir of youth” because it appeared to decline with age, and exogenous 
dosing reversed cardiac hypertrophy and improved skeletal muscle in aged animals [1, 12, 27]. 
Subsequent research questioned these initial conclusions, with disagreements arising regarding 
the quality and accuracy of the reagents and assays used in the experimental procedures as 
well as in the interpretation of the results [6, 20, 24]. Additionally, other groups investigating the 
effects of GDF11 on the hearts of aged mice did not find a regenerative effect [28].  
Understanding the in vivo effects of circulating and secreted TGF-beta family members 
such as GDF11 is difficult. Limitations and differences in observed results may occur due to 
recombinant protein activity, route of administration, bioavailability and dosing. Furthermore, the 
TGF-beta family is highly regulated by a variety of circulating and tissue factors which may alter 
effects or render it not bioavailable [23]. Presumably all of this variability in delivery may partly 
explain the varied observations across these different experimental systems. To date, the in 
vivo effects of secreted proteins including many TGF-beta superfamily members have been 
identified using injection of CHO cells selected to express high levels of specific recombinant 
protein into mice, a classic and powerful approach to evaluating the biological activity of a 
secreted protein,. This technique leads to sustained, high levels of protein and has been used to 
identify the cachexia-inducing effects of TNF/cachectin, Interferon-g, TGF-b, IL-6 and myostatin, 
all known mediators of muscle wasting [2, 14, 19, 29, 31]. Furthermore, such an approach has 
defined hepatotrophic activities of IP-10 and IL-6, anti-apoptotic effects of IL-6, and anti-
cachexia activity of follistatin in this fashion [4, 9-11, 29, 30], while others have examined bone 
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formation, tumorigenicity and tumor necrosis, angiogenesis and many other processes in this 
fashion [7, 22, 25, 26].  
Our data presented herein examined the effects of sustained GDF11 on heart and 
skeletal muscle using CHO cells that were transfected and selected to express high levels of 
GDF11. We demonstrate that sustained administration of GDF11 in mice injected with GDF11 
expressing cells, but not a variety of control cell lines, produces a systemic wasting syndrome 
resulting in atrophy of myocardium and skeletal muscle.  These data support a strong anti-
cardiomyocyte hypertrophic effect for GDF11. It also supports a role for GDF11 in skeletal 
muscle wasting, an effect suggested by Glass and others [6]. 
EXPERIMENTAL PROCEDURES 
Mice 
Male athymic nu/nu mice were from Harlan Laboratories, Inc. (Indianapolis, IN, USA). A 
CHO cell line stably producing GDF11 (CHO-GDF11) was obtained by transfection of the 
plasmid vector pMSXND containing full-length Gdf11 cDNA into DHFR-deficient CHO-DUXX 
cells and subsequent methotrexate selection. A similarly selected CHO cell line (CHO-control) 
not expressing detectable recombinant protein was used as a control. Expression of GDF11 
was confirmed by Western blotting of conditioned medium, partially purified fractions and serum 
using anti-GDF11 antibody MAB19581 (R&D Systems). 10-week old male mice were injected in 
the upper rear portion of the right hind limbs with PBS (normal), CHO-control (Control) or CHO-
GDF11 (GDF11) cells in 0.1 mL of PBS. Mice were euthanized at 10 days (Control and GDF11) 
or 13 days (normal, Control and GDF11).  Studies were done twice; there were no differences 
between the first and second trials and the second is reported here. Euthanasia was performed 
by exanguination through cardiac puncture followed by cervical dislocation and tissue collection 
under isoflurane general anesthesia. Muscles of the left hind limb as well as hearts were 
collected and weighed, then either snap frozen with liquid nitrogen or embedded in Tissue-Tek® 
OCT compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen in isopentane. Left 
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tibia length was measured. All experiments were approved by and performed per the guidelines 
of the Institutional Animal Care and Use Committees at Indiana University School of Medicine.  
 
Echocardiography 
Cardiac muscle dimensions and function were assessed at 8, 10, and 13 days after 
CHO cell injection via echocardiography using the Vevo® 2100 system (Fujifilm VisualSonics 
Inc., Toronto, Canada). Mice were placed under isoflurane anesthesia for the duration of the 
procedure, adjusting the level to maintain a heart rate of 400 – 500 beats per minute. Left 
ventricular dimensions and function were assessed by M-mode scanning of the left ventricular 
chamber. 
 
Electrocardiography 
Electrocardiogram (ECG) recordings were taken at 7, 9, and 13 days after CHO cell 
injection using the ECGenie apparatus (Mouse Specifics, Inc., Boston, MA, USA) as previously 
described [16]. Awake mice were placed on a platform with footplate electrodes that captures 
cardiac electrical activity with high fidelity. Several minutes of recording were obtained, and 
selected 1 – 5 second recordings of PQRST complexes were analyzed for various intervals 
using the eMouse signal analysis software (Mouse Specifics, Inc., Boston, MA, USA). Heart rate 
and heart rate variability (HRV), calculated as standard deviation of a mean 38 beats, were also 
obtained. 
 
Body composition analysis 
Lean and whole body fat masses were measured on awake mice at 9 and 13 days after 
CHO cell injection using an EchoMRI-500 (Echo Medical Systems, Houston, TX, USA). Two 
measurements were taken per mouse per analysis and averaged. 
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Grip strength measurement 
Grip strength was determined at 10 and 13 days after CHO cell injection using a force 
gauge (Extech Intruments, Nashua, NH, USA). Three measurements at each time point were 
averaged. 
 
Gene expression studies 
qRT-PCR was used to measure the mRNA expression levels of atrogin-1, MuRF1, Pax 
7, Mki67, Bnip3, Bnip3L, Myh6, Myh7, Anp, and Bnp in previously snap frozen mouse heart and 
quadriceps muscle. The total RNA extracted using the Qiagen miRNeasy Mini kit (Valencia, CA, 
USA) was quantified by NanoDrop (Thermo Scientific, Rockford, IL, USA), and the RNA integrity 
number was measured with Agilent RNA ScreenTape System (Agilent Technologies, Santa 
Clara, CA, USA). cDNA was synthesized by Thermo Scientific Verso cDNA synthesis kit. 
Primers were from Life Technologies. qRT-PCR was conducted on a Roche LightCycler 96 
Real-Time PCR System (Roche, Indianapolis, IN, USA) using TaqMan Universal Master Mix II, 
with UNG (Life Technologies, Grand Island, NY, USA) in a 20 μl final reaction mixture. The 
cycling conditions were as follows: preincubation at 95°C for 1 min and 50 cycles of 10 s at 
95 °C, and 1 min at 60 °C. Experiments were performed in triplicate for each sample. Results 
were normalized to either TBP or 18S, and fold difference was calculated by 2−ΔΔCt. 
 
Western blotting analysis 
Snap frozen mouse heart and quadriceps muscle were homogenized in modified RIPA 
buffer. Protein was quantified using Pierce BCA protein assay kit (Thermo Scientific, Rockford, 
IL, USA). Tissue homogenates were separated by polyacrylamide gel (Bio-Rad, Hercules, CA, 
USA) electrophoresis under reducing conditions and transferred to nitrocellulose membranes 
(Bio-Rad, Hercules, CA, USA). Immunoblotting used the following antibodies: LC3B (Sigma, 
Saint Louis, MO, USA); p62 (BD Biosciences, San Jose, CA, USA); pSMAD2, SMAD2, pAKT, 
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AKT, pFOXO3a, FOXO3a, p4E-BP1 70, p4E-BP1 65, p4E-BP1 37/46, 4E-BP1, ubiquitin, and 
GAPDH (Cell Signaling Technology, Danvers, MA, USA). Signal was detected by SuperSignal 
West Femto (Thermo Scientific, Rockford, IL, USA) or Odyssey CLx western blot detection 
system (Li-Cor, Lincoln, NE, USA). ImageJ (NIH, Bethesda, MD, USA) or Odyssey software 
was used for quantification, respectively. 
Detection of GDF11 in the circulation was by Western blotting as above of serially 
diluted serum, running the equivalent of 0.5ul of serum per lane. GDF11 was detected using 
anti-human GDF11/BMP11 MAB19581 (R&D Systems) 
 
Histology and immunofluorescence 
Snap frozen hearts were cut into 7 μm sections and stained with hematoxylin and eosin. 
Quantification of cardiomyocyte cross-sectional area (CSA) was measured by ImageJ (NIH, 
Bethesda, MD, USA). Measurements were obtained from ten, non-overlapping 20X fields per 
mouse. Means were calculated for each animal.  
Quadriceps was cut into 10 μm section, post-fixed in 4% paraformaldehyde (Affymetrix; 
Santa Clara, CA), blocked in 8% bovine serum albumin and reacted with anti-dystrophin 
antibody (1:400, Vector Laboratories; Burlingame, CA) overnight at 4° C. Sections were washed 
and incubated with a fluorescent secondary antibody (1:1000, Alexa Fluor® 594; Fisher 
Scientific) for one hour at room temperature. Sections were visualized using a fluorescent 
camera on an Observer.Z1 system (Zeiss; Oberkochen, Germany). Measurements were 
obtained from ten, non-overlapping 10X fields from each section by ImageJ macro (Minamoto et 
al., 2007). Mean cross sectional area was calculated for each animal and differences among 
groups (N=4 normal, N=4 Control, N=5 GDF11) were evaluated by one-way ANOVA. 
 
Statistical analyses 
 8	
Unpaired two-sample t-tests for two groups or one-way analysis of variance followed by Tukey’s 
multiple comparisons tests for more than two groups were used as appropriate to evaulate 
statistical significance with GraphPad Prism version 7, GraphPad Software, La Jolla California 
USA, www.graphpad.com. For cardiac parameters in Figure 2, results were tested for time 
dependence within groups by one-way ANOVA followed by test for linear trend and for the 
entire cohort with two-way ANOVA. 
 
RESULTS 
GDF11 Reduced Overall Body Weight and Organ Size 
Athymic nude mice were divided into three groups – a normal group, a control group in 
which CHO cells expressing no recombinant protein were injected, and an experimental group 
into which CHO cells expressing murine GDF11 were injected into the right hind limb (Figure 
S1). Tumors were visible by day 10 after injection and no differences in tumor mass were 
observed between groups (0.205 g ± 0.104 GDF11 vs. 0.206 g ± 0.089 control, NS). By day 9, 
body weights of GDF11 mice were significantly reduced compared to the control mice; this 
difference was even greater at day 13 (Figure 1, S1). Decreased whole body lean mass was not 
detected until day 13. There was no difference in percentage whole body fat mass measured 
between the groups. However, large differences in gross organ mass, including heart and 
skeletal muscle, were observed at necropsy (Figure S1-3). The differences in body and organ 
mass were due to weight loss, not suppression of growth because the control group did not 
grow over time and tibia length was not different among groups at euthanasia (Figure S1). 
Weights of kidney and liver were reduced by day 10, while weights of the carcass, epididymal 
fat pad, kidney and liver were reduced by day 13. Lungs and spleen were spared (Figure S2). 
Overall, circulating levels of GDF11 were increased approximately 37% overall compared 
with controls, as assessed by Western blotting of plasma (Figure S1). 
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GDF11 Reduced Heart Weight and Cardiomyocyte Size 
There are conflicting reports on the effects of GDF11 administration on mouse heart and 
cardiomyocyte size [12, 20, 28]. Here, GDF11 decreased heart mass by day 10.  Heart mass 
decreased 27% overall by day 13 (Figure 1A, B). Heart mass was decreased proportionately to 
total body mass (Figure 1C). Whole hearts and sections revealed visibly smaller organ and 
cardiomyocyte size in the GDF11 group (Figure 1D). Mean cardiomyocyte cross-sectional area 
was reduced approximately 35%, consistent with the Loffredo and Poggioli studies (Figure 1D-
F).  
 
GDF11 Altered Cardiac Proteolytic and Remodeling Pathways 
Expression of genes that normally compensate cardiac dysfunction was generally 
unchanged with GDF11. Anp and Bnp are typically increased in cardiac dysfunction and exert 
protective activities in cardiovascular homeostasis [18]. Activation of fetal gene expression, 
including Myh6 and Myh7 is also often observed in models of heart failure [5]. However, we did 
not find any changes in Anp, Myh6 (αMHC), or Myh7 (βMHC), similar to a recent study of 
GDF11 in aged mouse hearts [28]. While expression of Bnp at day 10 was increased in the 
GDF11 group, expression at day 13 was not significantly different (Figure 1G).  
GDF11 induced expression of ubiquitin-protein ligases atrogin-1/MAFbx/Fbxo32 and 
MuRF1/Trim63 at day 10 and MuRF1/Trim63 at day 13 [3, 8] (Figure 1G). Moreover, there was 
evidence of diminished cellular proliferation with decreased expression of Mki67 and potentially 
increased apoptosis and autophagy given increased expression of the pro-apoptotic and 
mitophagy-associated gene Bnip3 in the GDF11 mice at day 13. Differences in Bnip3L 
expression were not statistically significant following GDF11 exposure (Figure 1G). This 
expression profile suggests activation of proteolysis, apoptosis and autophagy by GDF11 in 
hearts. 
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Western blotting showed that GDF11 increased cardiac SMAD2 protein on day 13. 
Phosphorylated SMAD2 also appeared somewhat increased but this did not reach statistical 
significance (Figure 1H). Total protein ubiquitylation was increased 42% in GDF11 hearts 
compared to the control group (Figure S4). There were no statistically significant differences 
detected in levels of atrophy markers pFOXO3a, FOXO3a, p4E-BP1, or p62 (Figure S4). 
 
GDF11 Reduced Cardiac Size and Function 
Echocardiography supported our findings that GDF11 reduced heart size and also 
demonstrated reduced function. Cardiac size and dimensions were generally decreased in the 
GDF11 mice, where significant decreases in left ventricular internal diameter during diastole 
(LVIDd), posterior wall thickness during systole (PWTs), and left ventricular mass (LVM) were 
apparent by day 10, then later in posterior wall thickness during diastole (PWTd) by day 13 
(Figures 2A-C, S5). GDF11 also significantly decreased stroke volume (SV), ejection fraction 
(EF), and fractional shortening (FS) by day 10 (Figure 2D-F). Increasing time of GDF11 
exposure also correlated with increasing declines in both size (LVIDd, PWTd, PWTs, LVM) and 
functional measurements (SV, EF, FS) (Figure S6). No changes over time were noted in the 
control mice and measurements of normal and control mice were similar (Figures S6, S7). 
Electrocardiography was performed to measure heart rate and conductivity; however no 
differences were observed (Figure S8). 
 
GDF11 Decreased Skeletal Muscle Mass and Strength  
Muscle mass loss followed heart wasting, with individual muscles consistently decreased 
only on day 13 (Figures 3A-C). Grip strength in the GDF11 mice was also significantly 
decreased at day 13 (Figure 3D). Mean quadriceps myofiber cross-sectional area (CSA) of the 
GDF11 group was significantly smaller than controls at day 13 (Figure 3E-G).  
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GDF11 Induced Atrophy-Associated Pathways in Skeletal Muscle without Effects on Pax7 
GDF11 dramatically induced atrogin-1 and MuRF1 by day 13. Bnip3 expression tended 
to be increased in the GDF11 group, although Bnip3L was unchanged. Pax7 was similar 
between GDF11 and control mice, while Mki67 expression was significantly decreased. Thus 
GDF11-induced atrophy was apparently not accompanied by cell proliferation or compensatory 
regeneration (Figure 3H).  
Western blotting of quadriceps showed increased pSMAD2 with GDF11, while total 
SMAD2 was unchanged between GDF11 mice and controls and decreased compared to normal 
mice (Figure 4A). Phosphorylated and total AKT were unchanged, as were pFOXO3a and 
FOXO3a (Figure 4B), and FOXO1 was not detected. Expression of the translation repressor 4E-
BP1 was increased while its phosphorylated (inactive) forms were decreased by GDF11, 
suggesting that translation was inhibited (Figure 4C). Consistent with the trend towards 
increased Bnip3, levels of the autophagy proteins LC3-II, LC3-II/LC3-I, and p62 (Figure 4D) 
were increased by GDF11. Total protein ubiquitylation was also markedly increased (Figure 4E), 
consistent with the up-regulation of ubiquitin ligases atrogin-1/MAFbx and MuRF1 mRNAs. No 
increase in proteasome activity was detected at this time point, however. 
 
DISCUSSION 
Our results show that excess GDF11 in adult mice leads to cachexia, with consequential 
cardiac and skeletal muscle dysfunction and weakness. These results are consistent with 
shared structure and function to myostatin, which is 90% homologous, exerts similar wasting 
effects [29] and binds to the same receptor complex of type I (ALK5, ALK6) and type II 
(ACVR2A, ACVR2B) receptors. Activin A and Activin B in excess also produce a similar 
cachexia phenotype. Of these, thus far only Activin has been convincingly linked to a human 
cachexia condition, i.e. weight loss in cancer. However GDF11 has not been as carefully 
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studied in diseases associated with cardiac and muscle loss due to limitations in available 
assays. 
Initial studies [12, 27] showed that GDF11 declines with age, and that the reintroduction 
of this “elixir of youth” [1] reverses age-related degenerative changes in the body, including 
cardiac hypertrophy and skeletal muscle dysfunction/atrophy [12, 20, 27]. However in vivo 
studies by Smith et al. reported no changes in cardiac structure or function with GDF11 
administration [28]. Thus, we believe that the previous finding of cardiac hypertrophy reversal 
with GDF11 might not represent reversion to a normal cardiac phenotype, but rather induction of 
cardiac atrophy. Similarly, we also find that GDF11 overexpression leads to skeletal muscle 
wasting. 
There are conflicting research findings on body composition changes after GDF11 
administration. Poggioli et al. briefly mentioned weight loss in both young and old mice given 0.5 
mg/kg/day and/or 1 mg/kg/day of exogenous GDF11 but this finding was not explored in more 
detail [20]. Sinha et al. used 0.1 mg/kg/day and showed that body weight and muscle mass 
(tibialis and extensor digitorum longus) were unchanged in both young and old mice [27]. We 
find that GDF11 caused body weight loss, largely due to loss in lean mass. Skeletal muscle 
mass also significantly decreased with GDF11 overexpression. The differences between our 
study and Sinha et al. could potentially be attributed to differences in circulating GDF11 dose.  
There have also been conflicting findings on changes in the heart with GDF11 
administration.  Loffredo et al. showed that intraperitoneal GDF11 administration resulted in 
decreased heart weight and decreased cardiomyocyte cross-sectional area, but no difference in 
echocardiography compared to controls [12]. Similarly, Poggioli et al showed that for both young 
and old mice, intraperitoneal GDF11 administration decreased heart weight as well as cross-
sectional area of cardiomyocytes [20]. However, in the Smith et al. study, i.p. GDF11 
administration in 24 month old mice resulted in no differences in heart mass, echocardiography, 
terminal hemodynamic studies, cardiomyocyte cross-sectional area, or amount of fibrosis 
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compared to controls [28]. Our study supports that GDF11 promotes cardiac atrophy with 
corresponding decreases in both heart size and function.  
The mechanisms by which GDF11 activated cardiac wasting are unclear. Our results 
suggest enhanced autophagy and apoptosis, without altering expression of the genes that are 
typically induced in heart failure. In one study of failing hearts (presumably with a hypertrophic 
component), the investigators found that ANP levels are greater while αMHC and βMHC levels 
are decreased compared to non-failing hearts [21]. In another study, however, cardiac 
hypertrophy due to pressure overload was found to increase both αMHC and βMHC levels in 
cardiomyocytes [13]. While these studies differed in the direction of change in the cardiac 
markers, they nevertheless demonstrated that the levels of cardiac markers are changed by 
hypertrophic cardiac pathology. In accordance with Smith et al., we also found no differences in 
levels of cardiac markers (ANP, BNP, αMHC, and βMHC) that typically accompany pathologic 
hypertrophy [28],. These findings suggest that the atrophic effects of GDF11 likely do not act by 
diminishing pathologic cardiac hypertrophy. 
Regarding skeletal muscle regenerative potential, Sinha and Jang et al showed that 
GDF11 supplementation in old mice increased the frequency and function of muscle satellite 
cells as well as improved exercise endurance and grip strength [27]. Conversely, Egerman et al 
showed that GDF11 treatment did not affect regenerative capacity or cross-sectional area of 
skeletal muscle after injury; in fact, in vitro studies showed that GDF11 decreased the growth of 
adult and aged muscle satellite cells and did not change the expression of markers of muscle 
differentiation [6]. Our study observed that GDF11 activated muscle atrophy pathways, including 
autophagy and ubiquitylation, while inducing inhibitors of translation. This led to 20-30% 
decreased skeletal muscle mass and a corresponding ~20% decrease in myofiber cross 
sectional area. Consistent with reduced muscle mass, the grip strength measurements also 
declined. Unchanged Pax7 levels and decreased Ki67 expression suggests that GDF11 in this 
setting failed to activate regeneration. Muscle loss occurred later than heart wasting, suggesting 
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that there might be differences in sensitivity to GDF11 in cardiac versus skeletal muscle, with 
heart wasting induced at lower doses or shorter duration. Alternatively, wasting of skeletal 
muscle might have been initiated secondary to reductions in heart function. 
While this study contributes important evidence around GDF11 function, it has 
limitations. Our study used only 10-week old (young) mice, thus does not address aging. 
Although reliability of various quantification methods for GDF11 has been brought into question, 
Western blotting of plasma using an antibody validated to detect GDF11 showed that our 
intervention increased circulating GDF11 levels by approximately 40% [6, 20, 28], with several 
samples overlapping the range of normal. We cannot exclude the possibility of underlying, 
compensatory dysregulation of endogenous GDF11 expression or changes in expression of 
critical components of GDF11 regulation, including activating proteases, inhibitory binding 
proteins, receptors and signaling modulators. However, no prior studies have examined these in 
detail either, which is a general limitation of this field. Given its complex post-transcriptional 
regulation, indeed it is naïve to focus solely on mRNA and protein levels of GDF11 (REF). 
Overall, our data demonstrate that GDF11 administration to adult mice causes 
significant weight loss and cachexia, as well as cardiac and skeletal muscle dysfunction and 
weakness. Thus any endeavors to use GDF11 as a therapeutic agent should be approached 
with caution. 
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FIGURE LEGENDS 
 
Figure 1. Heart and Cardiomyocyte Size Decrease with GDF11 Overexpression 
(A and B) Heart weights (HW) of normal, control, and GDF11 mice at sacrifice, 
normalized to (A) initial body weight (IBW), (B) tibia length (TL), and (C) to final body 
weight (FBW). Heart weights of normal mice (n=4) taken at day 13 are shown to the left 
of the dashed vertical line, and those of control and GDF11 mice at day 10 (n=5 and 
n=8, respectively) and at day 13 (n=5 and n=7, respectively) are compared to the right 
of the line. Horizontal lines with error bars indicate mean ± SEM.  
(D) Gross anatomy (top row of figure on left, 5 mm scale bar) and hematoxylin and 
eosin staining (cross-section, middle row, 3 mm scale bar; 40x magnification, bottom 
row) of normal, control, and GDF11 mouse hearts at day 13. LV, left ventricle; RV, right 
ventricle. 
(E) Mean cardiomyocyte fiber cross-sectional area (CSA) of normal, control, and 
GDF11 mice at day 13. Data are mean ± SD.  
(F) Histogram of cardiomyocyte CSA for normal, control, and GDF11 mice at day 13. 
Numerical data of mean cardiomyocyte CSA (data are mean ± SEM) and number of 
fibers measured are shown in table below.  
(G) Gene expression analyses of cardiac muscle in normal (left of dashed vertical line, 
measured at day 13), control, and GDF11 mice at days 10 and 13. Data are 
represented as mean fold change ± SD. Fold change for atrogin-1 and MuRF1 were 
calculated using reference gene TBP, while data for all other genes were calculated 
using reference gene 18S.  
(H) Western blotting analyses to determine SMAD2 levels in normal, control, and 
GDF11 mice at day 13. Horizontal lines with error bars indicate mean ± SD.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) and p < 0.0001 (****). 
 
 
Figure 2. Echocardiographic Measurements in Mice with GDF11 Overexpression 
Demonstrate Reduced Cardiac Size and Function 
(A and B) Time course of echocardiographic dimension changes in control and GDF11 
mice. (A) Left ventricular internal diameter (diastole/systole) (LVIDd/s) and (B) posterior 
wall thickness (diastole/systole) (PWTd/s) measurements are shown. 
(C-F) Time course of changes in echocardiographic measurements of (C) left ventricle 
(LV) mass and cardiac function as measured by (D) stroke volume, (E) ejection fraction, 
and (F) fractional shortening. Horizontal lines with error bars indicate mean ± SD.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), and p < 
0.001 (***). 
 
 
Figure 3. Skeletal Muscle Weight and Function Decrease with GDF11 
Overexpression 
(A-C) Weights of the left hind limb (A) gastrocnemius, (B) quadriceps, and (C) tibialis 
muscles taken at sacrifice were reported as percentages of initial body weight (IBW). 
Muscle weights of normal mice (n=4) taken at day 13 are shown to the left of the 
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dashed vertical line, and those of control and GDF11 mice at day 10 (n=5 and n=8, 
respectively) and at day 13 (n=5 and n=7, respectively) are compared to the right of the 
line. Horizontal lines with error bars indicate mean ± SEM.  
(D) Grip strength measurements at day 10 and 13. Each data point is an average of 3 
separate measurements in each mouse. Horizontal lines with error bars indicate mean ± 
SEM.  
(E) Mean quadriceps myocyte fiber cross-sectional area (CSA) of normal, control, and 
GDF11 mice at day 13. Data are mean ± SD. 
(F) Histogram of quadriceps CSA for normal, control, and GDF11 mice at day 13. 
(G) Laminin staining (10x magnification, 100 μm scale bar) of left hind limb quadriceps 
muscle cross-sections in normal, control, and GDF11 mice at day 13. Numerical data of 
mean myocyte CSA (data are mean ± SEM) and number of fibers measured are shown 
in table below for N=4, 4, and 5 mice for normal, control and GDF11 mice respectively. 
(H) Gene expression analyses of quadriceps muscle in normal (left of dashed vertical 
line, measured at day 13), control, and GDF11 mice at days 10 and 13. Data are 
represented as mean fold change ± SD. All fold changes calculated using reference 
gene 18S.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**),p < 0.001 
(***), and p < 0.0001 (****). 
 
Figure 4. Protein Regulatory Pathways in Quadriceps of Mice with GDF11 
Overexpression Demonstrate Increased Degradation and Decreased Synthesis 
(A-E) Western blotting analyses to determine activation of (A) SMAD2 signaling, (B) 
hypertrophy/atrophy pathways (arrowhead points to FOXO3a), (C) protein translation 
and synthesis, (D) autophagy, and (E) ubiquitination in normal, control, and GDF11 
mice at day 13. Blots are presented on the left and protein levels quantified in graphs on 
the right. Horizontal lines with error bars indicate mean ± SD.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), and p < 
0.0001 (****). 
 
  
 21	
SUPPLEMENTAL FIGURES 
 
Figure S1. Overall Body Weight and Composition Decrease with GDF11 
Overexpression 
(A) Final body weights of normal, control, and GDF11 mice at sacrifice, reported as 
percentages of initial body weight (IBW). Final body weights of normal mice (n=4) taken 
at day 13 are shown to the left of the dashed vertical line, and those of control and 
GDF11 mice at day 10 (n=5 and n=8, respectively) and at day 13 (n=5 and n=7, 
respectively) are compared to the right of the line. Horizontal lines with error bars 
indicate mean ± SEM.  
(B) Fat mass (left panel) and lean mass (right panel) as measured by EchoMRI body 
composition analysis for normal, control, and GDF11 mice at days 9 and 13. Horizontal 
lines with error bars indicate mean ± SEM.  
(C) Body weight over time for the three cohorts. Differences were significant between 
GDF11 and the other two groups beginning at day 9 (P=0.02) and through day 13 
(P<0.001). 
(D) Control (left) and GDF11 (right) mice at euthanasia, juxtaposed to illustrate 
significant weight loss in GDF11 mice at day 15. 
Statistically significant differences are indicated at p < 0.01 (**) and p < 0.0001 (****). 
(E) Western blotting of 2.5 ul of plasma from mice euthanized at the indicated time point 
and of 10 ng recombinant human GDF11 (R & D Systems). (F) Quantification of blots 
was done separately for each time point, referencing the mean control value as 1 and 
the GDF11 values as a fold change over the mean control. Only when results from both 
comparisons, day 10 and day 13, were pooled were the results significantly different. 
Statistically significant difference is indicated at p < 0.05 (*). 
 
Figure S2. Reduced Organ Weights in Mice with GDF11 Overexpression 
(A) Organs at necropsy in normal, control, and GDF11 mice at day 15. H, heart; K, 
kidneys; G, gastrocnemius; T, tibialis; Q, quadriceps; S, spleen; L, liver. (B) Tibia length 
(not significantly different among groups), and (C) final body weight normalized to tibia 
length at euthanasia. Normal mice (n=4) taken at day 13 are shown to the left of the 
dashed vertical line, and those of control and GDF11 mice at day 10 (n=5 and n=8, 
respectively) and at day 13 (n=5 and n=7, respectively) are compared to the right of the 
line. Horizontal lines with error bars indicate mean ± SD. Statistically significant 
differences are indicated at p < 0.05 (*) and p < 0.0001 (****). 
 
Figure S3. Reduced Organ Weights in Mice with GDF11 Overexpression 
Weights of (A) carcasses and (B-F) various organs at sacrifice, reported as percentages 
of initial body weight (IBW). Final body weights of normal mice (n=4) taken at day 13 are 
shown to the left of the dashed vertical line, and those of control and GDF11 mice at 
day 10 (n=5 and n=8, respectively) and at day 13 (n=5 and n=7, respectively) are 
compared to the right of the line. Horizontal lines with error bars indicate mean ± SEM. 
Statistically significant differences are indicated at p < 0.05 (*), p < 0.001 (***), and p < 
0.0001 (****). 
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Figure S4. Protein Expression in Hearts of Mice with GDF11 Overexpression 
(A-C) Western blotting analyses to determine activation of (A) ubiquitylation, and (B-D) 
atrophy, protein translation and synthesis, and autophagy pathways in normal, control, 
and GDF11 mice at day 13. Blots are presented on the left and protein levels quantified 
in graphs on the right. Horizontal lines with error bars indicate mean ± SD. Statistically 
significant differences are indicated at p < 0.05 (*). 
 
Figure S5. Echocardiographic Images in Mice with GDF11 Overexpression 
Demonstrate Reduced Cardiac Size and Function 
(A and B) Brightness mode image views of control and GDF11 mouse hearts in the 
parasternal (A) long axis view of the left ventricle (outlined in gray) during systole and 
diastole and the (B) short axis view of the left ventricle at the papillary muscle level 
during systole, taken at day 13. AW, anterior wall; LV, left ventricle; PM, papillary 
muscle; PW, posterior wall. White scale bars on bottom left corner, 1 mm. 
(C) Motion mode imaging of control and GDF11 mouse hearts for left ventricular wall, 
chamber, and cardiac function measurements at day 13. LVIDd/s, left ventricular 
internal diameter (diastole/systole); PW, posterior wall. 
 
Figure S6. Statistical analysis of effects of time and treatment on 
echocardiography parameters. 
(A) One-way ANOVA for time effects within each group, followed by test for linear trend. 
(B) Two-way ANOVA for time (days 8, 10, and 13) and treatment (Control versus 
GDF11) for data in Figure 2. LVIDd,s left ventricular internal diameter in diastole or 
systole; PWTd,s posterior wall thickness in diastole or systole; LV left ventricular; SV 
stroke volume; EF ejection fraction; FS fractional shortening. p < 0.05 (*), p < 0.001 
(***), and p < 0.0001 (****). 
 
Figure S7. Echocardiography in Normal and Control Mice are Similar  
(A and B) Time course of echocardiographic dimension changes in normal and control 
mice. (A) Left ventricular internal diameter (diastole/systole) (LVIDd/s) and (B) posterior 
wall thickness (diastole/systole) (PWTd/s) measurements are shown. 
(C-F) Time course of changes in echocardiographic measurements of (C) left ventricle 
(LV) mass and cardiac function as measured by (D) stroke volume, (E) ejection fraction, 
and (F) fractional shortening. Horizontal lines with error bars indicate mean ± SD. 
Statistically significant differences are indicated at p < 0.05 (*) and p < 0.01 (**). The 
differences were in the normal mice at day 10 and day 13 versus baseline, not in the 
control mice which were unchanged over time. 
 
Figure S8. Electrocardiography is Unchanged in Mice with GDF11 Overexpression 
(A-I) Time course of electrocardiographic measurements of normal (n=4), control (n=10, 
days 7 and 9; n=5, day 13), and GDF11 (n=16, days 7 and 9; n=8, day 13) mice. Data 
points represent mean ± SD. Statistically significant difference is indicated at p < 0.05 
(*). 
 
 
Figure 1. Heart and Cardiomyocyte Size Decrease with GDF11 Overexpression 
(A and B) Heart weights (HW) of normal, control, and GDF11 mice at sacrifice, normalized to 
(A) initial body weight (IBW), (B) tibia length (TL), and (C) to final body weight (FBW). Heart 
weights of normal mice (n=4) taken at day 13 are shown to the left of the dashed vertical line, 
and those of control and GDF11 mice at day 10 (n=5 and n=8, respectively) and at day 13 (n=5 
and n=7, respectively) are compared to the right of the line. Horizontal lines with error bars 
indicate mean ± SEM.  
(D) Gross anatomy (top row of figure on left, 5 mm scale bar) and hematoxylin and eosin 
staining (cross-section, middle row, 3 mm scale bar; 40x magnification, bottom row) of normal, 
control, and GDF11 mouse hearts at day 13. LV, left ventricle; RV, right ventricle. 
(E) Mean cardiomyocyte fiber cross-sectional area (CSA) of normal, control, and GDF11 mice at 
day 13. Data are mean ± SD.  
(F) Histogram of cardiomyocyte CSA for normal, control, and GDF11 mice at day 13. Numerical 
data of mean cardiomyocyte CSA (data are mean ± SEM) and number of fibers measured are 
shown in table below.  
(G) Gene expression analyses of cardiac muscle in normal (left of dashed vertical line, 
measured at day 13), control, and GDF11 mice at days 10 and 13. Data are represented as 
mean fold change ± SD. Fold change for atrogin-1 and MuRF1 were calculated using reference 
gene TBP, while data for all other genes were calculated using reference gene 18S.  
(H) Western blotting analyses to determine SMAD2 levels in normal, control, and GDF11 mice 
at day 13. Horizontal lines with error bars indicate mean ± SD.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and 
p < 0.0001 (****). 
 
 
Figure 2. Echocardiographic Measurements in Mice with GDF11 Overexpression 
Demonstrate Reduced Cardiac Size and Function 
(A and B) Time course of echocardiographic dimension changes in control and GDF11 mice. (A) 
Left ventricular internal diameter (diastole/systole) (LVIDd/s) and (B) posterior wall thickness 
(diastole/systole) (PWTd/s) measurements are shown. 
(C-F) Time course of changes in echocardiographic measurements of (C) left ventricle (LV) 
mass and cardiac function as measured by (D) stroke volume, (E) ejection fraction, and (F) 
fractional shortening. Horizontal lines with error bars indicate mean ± SD.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). 
 
 
Figure 3. Skeletal Muscle Weight and Function Decrease with GDF11 Overexpression 
(A-C) Weights of the left hind limb (A) gastrocnemius, (B) quadriceps, and (C) tibialis muscles 
taken at sacrifice were reported as percentages of initial body weight (IBW). Muscle weights of 
normal mice (n=4) taken at day 13 are shown to the left of the dashed vertical line, and those of 
control and GDF11 mice at day 10 (n=5 and n=8, respectively) and at day 13 (n=5 and n=7, 
respectively) are compared to the right of the line. Horizontal lines with error bars indicate mean 
± SEM.  
(D) Grip strength measurements at day 10 and 13. Each data point is an average of 3 separate 
measurements in each mouse. Horizontal lines with error bars indicate mean ± SEM.  
(E) Mean quadriceps myocyte fiber cross-sectional area (CSA) of normal, control, and GDF11 
mice at day 13. Data are mean ± SD. 
(F) Histogram of quadriceps CSA for normal, control, and GDF11 mice at day 13. 
(G) Laminin staining (10x magnification, 100 μm scale bar) of left hind limb quadriceps muscle 
cross-sections in normal, control, and GDF11 mice at day 13. Numerical data of mean myocyte 
CSA (data are mean ± SEM) and number of fibers measured are shown in table below for N=4, 
4, and 5 mice for normal, control and GDF11 mice respectively. 
(H) Gene expression analyses of quadriceps muscle in normal (left of dashed vertical line, 
measured at day 13), control, and GDF11 mice at days 10 and 13. Data are represented as 
mean fold change ± SD. All fold changes calculated using reference gene 18S.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**),p < 0.001 (***), and 
p < 0.0001 (****). 
 
Figure 4. Protein Regulatory Pathways in Quadriceps of Mice with GDF11 
Overexpression Demonstrate Increased Degradation and Decreased Synthesis 
(A-E) Western blotting analyses to determine activation of (A) SMAD2 signaling, (B) 
hypertrophy/atrophy pathways (arrowhead points to FOXO3a), (C) protein translation and 
synthesis, (D) autophagy, and (E) ubiquitination in normal, control, and GDF11 mice at day 13. 
Blots are presented on the left and protein levels quantified in graphs on the right. Horizontal 
lines with error bars indicate mean ± SD.  
Statistically significant differences are indicated at p < 0.05 (*), p < 0.01 (**), and p < 0.0001 
(****). 
 
  
 Figure S1. Overall Body Weight and Composition Decrease with GDF11 Overexpression 
(A) Final body weights of normal, control, and GDF11 mice at sacrifice, reported as percentages 
of initial body weight (IBW). Final body weights of normal mice (n=4) taken at day 13 are shown 
to the left of the dashed vertical line, and those of control and GDF11 mice at day 10 (n=5 and 
n=8, respectively) and at day 13 (n=5 and n=7, respectively) are compared to the right of the 
line. Horizontal lines with error bars indicate mean ± SEM.  
(B) Fat mass (left panel) and lean mass (right panel) as measured by EchoMRI body 
composition analysis for normal, control, and GDF11 mice at days 9 and 13. Horizontal lines 
with error bars indicate mean ± SEM.  
(C) Body weight over time for the three cohorts. Differences were significant between GDF11 
and the other two groups beginning at day 9 (P=0.02) and through day 13 (P<0.001). 
(D) Control (left) and GDF11 (right) mice at euthanasia, juxtaposed to illustrate significant 
weight loss in GDF11 mice at day 15. 
Statistically significant differences are indicated at p < 0.01 (**) and p < 0.0001 (****). 
 
Figure S2. Reduced Organ Weights in Mice with GDF11 Overexpression 
(A) Organs at necropsy in normal, control, and GDF11 mice at day 15. H, heart; K, kidneys; G, 
gastrocnemius; T, tibialis; Q, quadriceps; S, spleen; L, liver. (B) Tibia length (not significantly 
different among groups), and (C) final body weight normalized to tibia length at euthanasia. 
Normal mice (n=4) taken at day 13 are shown to the left of the dashed vertical line, and those of 
control and GDF11 mice at day 10 (n=5 and n=8, respectively) and at day 13 (n=5 and n=7, 
respectively) are compared to the right of the line. Horizontal lines with error bars indicate mean 
± SD. Statistically significant differences are indicated at p < 0.05 (*) and p < 0.0001 (****). 
 
 
Figure S3. Reduced Organ Weights in Mice with GDF11 Overexpression 
Weights of (A) carcasses and (B-F) various organs at sacrifice, reported as percentages of 
initial body weight (IBW). Final body weights of normal mice (n=4) taken at day 13 are shown to 
the left of the dashed vertical line, and those of control and GDF11 mice at day 10 (n=5 and 
n=8, respectively) and at day 13 (n=5 and n=7, respectively) are compared to the right of the 
line. Horizontal lines with error bars indicate mean ± SEM. Statistically significant differences 
are indicated at p < 0.05 (*), p < 0.001 (***), and p < 0.0001 (****). 
 
 
Figure S4. Protein Expression in Hearts of Mice with GDF11 Overexpression 
(A-C) Western blotting analyses to determine activation of (A) ubiquitylation, and (B-D) atrophy, 
protein translation and synthesis, and autophagy pathways in normal, control, and GDF11 mice 
at day 13. Blots are presented on the left and protein levels quantified in graphs on the right. 
Horizontal lines with error bars indicate mean ± SD. Statistically significant differences are 
indicated at p < 0.05 (*). 
 
 
Figure S5. Echocardiographic Images in Mice with GDF11 Overexpression Demonstrate 
Reduced Cardiac Size and Function 
(A and B) Brightness mode image views of control and GDF11 mouse hearts in the parasternal 
(A) long axis view of the left ventricle (outlined in gray) during systole and diastole and the (B) 
short axis view of the left ventricle at the papillary muscle level during systole, taken at day 13. 
AW, anterior wall; LV, left ventricle; PM, papillary muscle; PW, posterior wall. White scale bars 
on bottom left corner, 1 mm. 
(C) Motion mode imaging of control and GDF11 mouse hearts for left ventricular wall, chamber, 
and cardiac function measurements at day 13. LVIDd/s, left ventricular internal diameter 
(diastole/systole); PW, posterior wall. 
 
Figure S6. Statistical analysis of effects of time and treatment on echocardiography 
parameters. 
(A) One-way ANOVA for time effects within each group, followed by test for linear trend. (B) 
Two-way ANOVA for time (days 8, 10, and 13) and treatment (Control versus GDF11) for data 
in Figure 2. LVIDd,s left ventricular internal diameter in diastole or systole; PWTd,s posterior 
wall thickness in diastole or systole; LV left ventricular; SV stroke volume; EF ejection fraction; 
FS fractional shortening. p < 0.05 (*), p < 0.001 (***), and p < 0.0001 (****). 
 
Figure S7. Echocardiography in Normal and Control Mice are Similar  
(A and B) Time course of echocardiographic dimension changes in normal and control mice. (A) 
Left ventricular internal diameter (diastole/systole) (LVIDd/s) and (B) posterior wall thickness 
(diastole/systole) (PWTd/s) measurements are shown. 
(C-F) Time course of changes in echocardiographic measurements of (C) left ventricle (LV) 
mass and cardiac function as measured by (D) stroke volume, (E) ejection fraction, and (F) 
fractional shortening. Horizontal lines with error bars indicate mean ± SD. Statistically significant 
differences are indicated at p < 0.05 (*) and p < 0.01 (**). The differences were in the normal 
mice at day 10 and day 13 versus baseline, not in the control mice which were unchanged over 
time. 
 
Figure S8. Electrocardiography is Unchanged in Mice with GDF11 Overexpression 
(A-I) Time course of electrocardiographic measurements of normal (n=4), control (n=10, days 7 
and 9; n=5, day 13), and GDF11 (n=16, days 7 and 9; n=8, day 13) mice. Data points represent 
mean ± SD. Statistically significant difference is indicated at p < 0.05 (*). 
 
 
Figure S9. Western blotting for GDF11 in plasma 
 
(A) Western blotting of 2.5 ul of plasma from mice euthanized at the indicated time point and of 
10 ng recombinant human GDF11 (R & D Systems). (B) Quantification of blots was done 
separately for each time point, referencing the mean control value as 1 and the GDF11 values 
as a fold change over the mean control. Only when results from both comparisons, day 10 and 
day 13, were pooled were the results significantly different. Statistically significant difference is 
indicated at p < 0.05 (*). 
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Figure S6 
A  
One-way ANOVA for time effects within each group, followed by test for linear trend. 
 Control GDF11 
 
P-value 
time Slope 
P-value 
trend 
P-value 
time d Slope 
P-value 
trend 
LVIDd ns   ns * -0.147 * 
LVIDs ns   ns ns   ns 
PWTd ns  ns ns -0.029 * 
PWTs ns   ns *** -0.066 *** 
LV mass ns  ns *** -6.447 *** 
SV ns   ns ** -5.57 *** 
EF ns  ns * -4.251 * 
FS ns   ns * -2.332 * 
 
B  
Two-way ANOVA for time (days 8, 10, and 13) and treatment (Control versus GDF11) for data in 
Figure 2. 
  P value % of total variation 
  Interaction Time Treatment Interaction Time Treatment 
LVIDd ns ns **     13.87 
LVIDs ns ns ns       
PWTd ns ns **   16.34 
PWTs ** ns **** 13.08   29.22 
LV mass ** ns **** 12.73  26.63 
SV ** * **** 10.37 9.63 24.34 
EF ns ns **   15.73 
FS ns ns **     15.7 
 
LVIDd,s left ventricular internal diameter in diastole or systole; PWTd,s posterior wall thickness in 
diastole or systole; LV left ventricular; SV stroke volume; EF ejection fraction; FS fractional 
shortening. p < 0.05 (*), p < 0.001 (***), and p < 0.0001 (****). 
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